| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Nuclear Medicine Department, Clinical Center [M. J., R. N., C. P., M. J. P-B.], National Cancer Institute [J. S., W. v. O., J. N. W.], NIH, Bethesda, Maryland 20892, and Takeda, Inc., Osaka, Japan [J. S.]
Monoclonal antibodies (MAbs) often distribute nonuniformly in tumors. In part, that observation reflects intrinsic heterogeneity within the tumor; in part, it reflects poor penetration through tumor substance. Several years ago, we proposed the "binding site barrier" hypothesis (J. N. Weinstein, R. R. Eger, D. G. Covell, C. D. V. Black, J. Mulshine, J. A. Carrasquillo, S. M. Larson, and A. M. Keenan, Ann. NY Acad. Sci., 507: 199–210, 1987; K. Fujimori, D. C. Covell, J. E. Fletcher, and J. N. Weinstein, Cancer Res., 49: 5656–5663, 1989), the idea that antibodies (and other ligands) could be prevented from penetrating tumors by the very fact of their successful binding to target antigen. Calculations suggested that this might be a significant factor in the therapy of even microscopic nodules. The higher the affinity and the higher the antigen density, the greater the barrier. Here, we provide direct experimental evidence of such a barrier to the percolation of D3 MAb through intradermally implanted line 10 carcinoma of guinea pigs. After affinity purification using glutaraldehyde-fixed line 10 cells, the D3 had an average immunoreactivity of 88%, a binding constant of 1.6 ± 0.3 (SEM) x 1010 M-1, and saturation binding of 355,000 ± 15,000 molecules/cell. Using a combination of double-label autoradiography and double-chromagen immunohistochemistry, we determined simultaneously the distribution of (a) i.v. injected D3 MAb; (b) coinjected isotype-matched control IgG (BL3); (c) D3 antigen; (d) blood vessels. The previously developed mathematical models aided in the design of these experiments. Double immunochemical staining of the tumors showed antigen-rich patches 100–800 µm across, surrounded by blood vessels. At a low MAb dose (30 µg), binding to antigen severely hindered penetration into antigenic patches as small as 200 µm, even at 72 h. Explanation of this finding by a physical barrier was ruled out by the observation that BL3 distributed uniformly in the same patches. At a higher dose (1000 µg), the binding site barrier could be partially overcome. The same general principles of micropharmacology may apply to biological ligands other than antibodies, including those secreted by genetically modified cells.
1 To whom requests for reprints should be addressed, at 9000 Rockville Pike, National Cancer Institute/NIH, Building 10, Room 4B-54, Bethesda, MD 20892.
Received 1/ 6/92. Accepted 7/27/92.
This article has been cited by other articles:
|
|
 |
|
  J. H.E. Baker, K. E. Lindquist, L. A. Huxham, A. H. Kyle, J. T. Sy, and A. I. Minchinton Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts Clin. Cancer Res., April 1, 2008; 14(7): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. El Emir, U. Qureshi, J. L.J. Dearling, G. M. Boxer, I. Clatworthy, A. A. Folarin, M. P. Robson, S. Nagl, M. A. Konerding, and R. B. Pedley Predicting Response to Radioimmunotherapy from the Tumor Microenvironment of Colorectal Carcinomas Cancer Res., December 15, 2007; 67(24): 11896 - 11905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, L. Xiang, R. Hassan, and I. Pastan Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors PNAS, October 23, 2007; 104(43): 17099 - 17104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Dreher and A. Chilkoti Toward a Systems Engineering Approach to Cancer Drug Delivery J Natl Cancer Inst, July 4, 2007; 99(13): 983 - 985. [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Hicke, A. W. Stephens, T. Gould, Y.-F. Chang, C. K. Lynott, J. Heil, S. Borkowski, C.-S. Hilger, G. Cook, S. Warren, et al. Tumor Targeting by an Aptamer J. Nucl. Med., April 1, 2006; 47(4): 668 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Dreher, W. Liu, C. R. Michelich, M. W. Dewhirst, F. Yuan, and A. Chilkoti Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst, March 1, 2006; 98(5): 335 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Flessner, J. Choi, K. Credit, R. Deverkadra, and K. Henderson Resistance of Tumor Interstitial Pressure to the Penetration of Intraperitoneally Delivered Antibodies into Metastatic Ovarian Tumors Clin. Cancer Res., April 15, 2005; 11(8): 3117 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lu, J. Shen, M. D. Vil, H. Zhang, X. Jimenez, P. Bohlen, L. Witte, and Z. Zhu Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity J. Biol. Chem., October 31, 2003; 278(44): 43496 - 43507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Graff and K. D. Wittrup Theoretical Analysis of Antibody Targeting of Tumor Spheroids: Importance of Dosage for Penetration, and Affinity for Retention Cancer Res., March 15, 2003; 63(6): 1288 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Juweid Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice J. Nucl. Med., November 1, 2002; 43(11): 1507 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Bera, J. Williams-Gould, R. Beers, P. Chowdhury, and I. Pastan Bivalent Disulfide-stabilized Fragment Variable Immunotoxin Directed against Mesotheliomas and Ovarian Cancer Mol. Cancer Ther., December 1, 2001; 1(2): 79 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Kuszyk, F. M. Corl, F. N. Franano, D. A. Bluemke, L. V. Hofmann, B. J. Fortman, and E. K. Fishman Tumor Transport Physiology: Implications for Imaging and Imaging-Guided Therapy Am. J. Roentgenol., October 1, 2001; 177(4): 747 - 753. [Full Text] [PDF]
|
|
|
|
 |
|
 S. McGuire and F. Yuan Quantitative analysis of intratumoral infusion of color molecules Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H715 - H721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Adams, R. Schier, A. M. McCall, H. H. Simmons, E. M. Horak, R. K. Alpaugh, J. D. Marks, and L. M. Weiner High Affinity Restricts the Localization and Tumor Penetration of Single-Chain Fv Antibody Molecules Cancer Res., June 1, 2001; 61(12): 4750 - 4755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. McCall, L. Shahied, A. R. Amoroso, E. M. Horak, H. H. Simmons, U. Nielson, G. P. Adams, R. Schier, J. D. Marks, and L. M. Weiner Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity J. Immunol., May 15, 2001; 166(10): 6112 - 6117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schuhmacher, S. Kaul, G. Klivényi, H. Junkermann, A. Magener, M. Henze, J. Doll, U. Haberkorn, F. Amelung, and G. Bastert Immunoscintigraphy with Positron Emission Tomography: Gallium-68 Chelate Imaging of Breast Cancer Pretargeted with Bispecific Anti-MUC1/Anti-Ga Chelate Antibodies Cancer Res., May 1, 2001; 61(9): 3712 - 3717. [Abstract] [Full Text]
|
|
|
|
|
|
L. S. Zuckier, E. Z. Berkowitz, R. J. Sattenberg, Q. H. Zhao, H. F. Deng, and M. D. Scharff Influence of Affinity and Antigen Density on Antibody Localization in a Modifiable Tumor Targeting Model Cancer Res., December 1, 2000; 60(24): 7008 - 7013. [Abstract] [Full Text]
|
|
|
|
|
|
X.-Y. Zhang, J. Luck, M. W. Dewhirst, and F. Yuan Interstitial hydraulic conductivity in a fibrosarcoma Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2726 - H2734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Behr, R. D. Blumenthal, S. Memtsoudis, R. M. Sharkey, S. Gratz, W. Becker, and D. M. Goldenberg Cure of Metastatic Human Colonic Cancer in Mice with Radiolabeled Monoclonal Antibody Fragments Clin. Cancer Res., December 1, 2000; 6(12): 4900 - 4907. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ruan, J. A. O'Donoghue, S. M. Larson, R. D. Finn, A. Jungbluth, S. Welt, and J. L. Humm Optimizing the Sequence of Combination Therapy with Radiolabeled Antibodies and Fractionated External Beam J. Nucl. Med., November 1, 2000; 41(11): 1905 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. G. Stroomer, J. C. Roos, M. Sproll, J. J. Quak, K.-H. Heider, B. J. Wilhelm, J. A. Castelijns, R. Meyer, M. O. Kwakkelstein, G. B. Snow, et al. Safety and Biodistribution of 99mTechnetium-labeled Anti-CD44v6 Monoclonal Antibody BIWA 1 in Head and Neck Cancer Patients Clin. Cancer Res., August 1, 2000; 6(8): 3046 - 3055. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Mano, H. Suzuki, T. Terasaki, T. Iwahashi, K.-I. Ono, M. Naito, T. Tsuruo, and Y. Sugiyama Kinetic Analysis of the Disposition of MRK16, an Anti-P-glycoprotein Monoclonal Antibody, in Tumors: Comparison Between in Vitro and in Vivo Disposition J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 391 - 401. [Abstract] [Full Text]
|
|
|
|
|
|
D. A. Berk, F. Yuan, M. Leunig, and R. K. Jain Direct in vivo measurement of targeted binding in a human tumor xenograft PNAS, March 4, 1997; 94(5): 1785 - 1790. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
